REMARKS

The foregoing amendments in the specification and claims are of formal nature, and do not add new matter. Entry of the following amendments is requested.

<u>Amendments to the specification</u>

Table 1 has been amended to correct errors in the various sequences. The amendments to Table 1 correct errors in the sequence of the CDR regions of antibody molecules for which the complete VH and VL domain sequences that contain the correct CDR sequences are disclosed in the application as originally filed. Support for amended BAK1167F2 HCDR3 can be found in SEQ ID NO:35 on page 130 and support for amended BAK1167F2 LCDR1 can be found in SEQ ID NO:36 on page 130. Support for amended BAK1105H3 HCDR3 can be found in SEQ ID NO:39 on page 130 and support for amended BAK1105H3 LCDR1 can be found in SEQ ID NO:40 on page 131. Support for amended BAK1111D10 HCDR3 can be found in SEQ ID NO:41 on page 131 and support for amended BAK1111D10 LCDR1 can be found in SEQ ID NO:42 on page 131. Support for amended BAK1166G2 HCDR3 can be found in SEQ ID NO:53 on page 133 and support for amended BAK1166G2 LCDR1 can be found in SEQ ID NO:54 on page 133. Support for amended BAK1167F4 HCDR3 can be found in SEQ ID NO:43 on page 131 and support for amended BAK1167F4 LCDR1 can be found in SEQ ID NO:44 on page 131.

Support for the amendment on page 127, line 3, of "CDR2-SEQ ID NO 2: WISANNGDTNYGQEFQG" is supported by SEQ ID NO 13 on page 127.

Support for the amendment on page 127, line 13, of "CDR2-SEQ ID NO 8: WISANNGDTNYGQEFQG" is found in SEQ ID NO 15 on page 128.

Support for the amendment on page 133, line 33, of "CDR2-SEQ ID NO 62: WISANNGDTNYGQEFQG" is found in SEQ ID NO 35 on page 130.

Support for the amendment on page 134, line 9, of "CDR2-SEQ ID NO 68: WISANNGDTNYGQEFQG" is found in SEQ ID NO 53 on page 133.

Support for the amendment on page 134, line 19, of "CDR2-SEQ ID NO 74: WISGSNGYTSYGQEFQG" is found in SEQ ID NO 45, on page 131-132.

Support for the amendment on page 134, line 29, of "CDR2-SEQ ID NO 80: WINDATGDTQYGQEFQG" is found in SEQ ID NO 47 on page 132.

-14-

Support for the amendment on page 135, line 8, of "CDR2-SEQ ID NO 86: WISANNGDTNYGQEFQG" is found in SEQ ID NO 43, on page 131.

Support for the amendment on page 135, line 18, of "CDR2-SEQ ID NO 92: WIATPDGQTSYGQEFQG" and "CDR3- SEQ ID NO93: DSNSSWARWFFDL" is found in SEQ ID NO 41 on page 31.

Support for the amendment on page 135, line 28, of "CDR2-SEQ ID NO 98: WINYDGGNTQYGQEFQG" is found in SEQ ID NO 37, on page 130.

Applicants enclose a revised Sequence Listing which contains amendments to sequences 2, 8, 62, 68, 74, 80, 86, 92, 93 and 98.

Amendments to the claims

Prior to the present amendment, Claims 1-91 were pending in the application. After the amendment, Claims 1-34, 41-58, and 61 are pending in the application. Applicants have canceled Claims 2, 35-40, 69-60 and 62-91 and amended claims 1, 3, 9, and 14 without prejudice to filing a continuation/divisional/continuation-in-part application directed to the canceled subject matter. Support for the amendment to claim 1 can be found, for example, in the specification and in original claim 3.

CONCLUSION

Applicants believe that this application is in condition for allowance and request an early allowance.

-15-

Although no fees are believed to be due at this time, please charge any additional fees, including any fees for extension of time, or credit overpayment to Deposit Account No. **08-1641** (referencing Attorney's Docket No. **43518-0001 PC US**).

Please direct any calls in connection with this application to the undersigned at the number provided below.

Respectfully submitted,

Date: June 22, 2007   By:_____
                                                           Leslie A. Mooi (Reg. No. 37,047)

HELLER EHRMAN LLP
275 Middlefield Road
Menlo Park, California 94025
Telephone: (650) 324-7000
Facsimile: (650) 324-0638

SV 2284421 v1
6/22/07 1:32 PM (43518.0001)

Table 1

The following table lists antibody clones by Kabat numbering with amino acid substitutions in the heavy-chain CDRs (HCDR1, HCDR2, HCDR3), a linker, and light-chain CDRs (LCDR1, LCDR2, LCDR3), together with their Mean TF1 (nM) values and number of TF1 replicates (TF1 reps). The germline reference residues are shown in the header/reference row (BAK0278D6).

Germline reference residues (row BAK0278D6):
- HCDR1 (31–35): N Y G L S
- HCDR2 (50, 51, 52, 52A, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65): W I S A N N G D T N Y G Q E F Q G
- HCDR3 (96, 97, 98, 99, 100, 100A, 100B, 100C, 100D, 100E, 101, 102): D S S N W A R W F F D L
- LCDR1 (24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34): G G N N I G S K L V H
- LCDR2 (50, 51, 52, 53, 54, 55, 56): D D G D R P S
- LCDR3 (89, 90, 91, 92, 93, 94, 95, 95A, 95B, 96, 97): Q V W D T G S D P V V

Kabat numbering	(col)	Mean TF1 (nM)	TF1 reps
BAK0278D6		44	
BAK0500G9	PD	8	2
BAK1187B4	PD	0.1	2
BAK1167F2	PD	0.2	3
BAK1105H3	PD	0.2	2
BAK1185E1	PD	0.2	2
BAK1111D10	PD	0.2	2
BAK1184G5	PD	0.2	2
BAK1166G2	PD	0.2	2
BAK1184C8	PD	0.2	2
BAK1185F8	PD	0.2	2
BAK1167F4	PD	0.2	2
BAK1109G06	PD	0.3	2
BAK1183H4	PD	0.3	2
BAK1183D2	PD	0.3	2
BAK1184F9	PD	0.3	3
BAK1103G08	PD	0.3	2
BAK1157D08	PD	0.3	2
BAK1183B5	PD	0.3	2
BAK1097H06	PD	0.4	2
BAK1106F04	PD	0.4	2
BAK1183G5	PD	0.5	2
BAK1161H07	PD	0.6	1
BAK1162G04	PD	0.6	1
BAK1161D07	PD	0.6	1
BAK1162D09	PD	0.8	1
BAK1108F05	PD	0.9	1
BAK1107F08	PD	0.9	1
ALA VL26L	O	1.4	1
ALA VL26M	O	1.5	1
ALA VL26C	O	2.5	1
ALA VL26V	O	2.5	1
ALA VL26Y	O	2.9	1
ALA VL26F	O	3.1	1
ALA VL26R	O	3.5	1
ALA VL26T	O	3.8	1
BAK1001C10	O	3.9	1
BAK1018G7	RD	4.3	1
BAK1008C3	RD	4.5	2
BAK1009A4	RD	5.2	2
BAK1010D2	RD	5.3	2
BAK1007F9	RD	5.4	2
BAK1010H9	RD	6.4	1
BAK1008D2	RD	6.8	2
ALA VL26A	O	6.9	2
BAK1007C4	RD	7.2	1
ALA VL26H	O	7.6	1
BAK1054C3	RD	7.7	2
BAK1050G7	RD	9.3	2
BAK1016F8	RD	9.5	1
BAK1050D2	RD	10.0	1
BAK1060F6	RD	10.8	1
BAK1021D5	RD	11.7	1
BAK1062E10	RD	12.0	1
ALA VL26G	O	14.4	1
BAK1020C6	RD	15.0	1
BAK1022G9	RD	17.0	1
BAK1063G4	RD	17.0	1

Table 1 (cont'd)

Kabat numbering	HCDR1	HCDR2	HCDR3	linker	LCDR1	LCDR2	LCDR3	Mean TF1 (nM)	TF1 reps
BAK27B08								44	
BAK02C09								8	
BAK1063F1 (RD)								20.0	1
BAK049498 (PD)								21.8	4
BAK1010C5 (RD)								22.0	1
BAK049GH4 (PD)								22.0	3
BAK050186 (PD)								22.8	2
BAK1049D7 (RD)								23.0	1
BAK053IE2 (PD)								23.2	3
BAK043C4 (PD)								25.3	4
BAK1008E9 (RD)								27.0	1
BAK048908 (PD)								28.2	5
BAK042E5 (PD)								29.3	3
BAK1047E3 (RD)								30.0	1
BAK047D7 (PD)								31.0	4
BAK1008A7 (RD)								32.0	1
BAK1063H4 (RD)								34.0	1
BAK049544 (PD)								34.6	5
BAK078205 (PD)								39.0	1
1K050ZC3 (PD)								39.3	3
4K1007H6 (RD)								40.5	2
BAK1049G1 (RD)								45.0	1
BAK048482 (PD)								46.0	1
BAK050205 (PD)								28.6	5
								29.3	4
Phage Display = PD									
Ribosome Display = RD									
Point mutations = O									
Germlining = GL									